
Advanced therapy medicinal products (ATMPs) — gene therapies, somatic-cell therapies and tissue-engineered products — are among the most complex products to bring to the European[…]

Real-world evidence (RWE) has moved from the margins of EU medicines regulation to its core. Through initiatives such as DARWIN EU, the European Medicines Agency[…]

External reference pricing (ERP) sits at the heart of how medicine prices are set in Greece. For any company launching a product, understanding how the[…]

The pharmacovigilance system master file (PSMF) is the single document that describes how a marketing authorisation holder runs its safety system — and it is[…]

After more than two years of negotiation, the European Union has settled the text of its new pharmaceutical legislation — the most significant overhaul of[…]

The medical device transition has moved from a cliff edge to a staged runway — but the conditions attached to those extensions have already passed,[…]

Clawback is the single biggest commercial variable in the Greek pharmaceutical market. The rules for the rest of this decade were quietly rewritten in late[…]

When a payer cannot be certain a medicine is worth its price, the answer is increasingly not “no” — it is a contract that shares[…]

Orphan designation is one of the most valuable regulatory assets in Europe — and the rules that govern it are about to change for the[…]

A Risk Management Plan is not a formality appended to a dossier. It is the document in which you commit, in writing, to how a[…]